281 related articles for article (PubMed ID: 16430111)
1. [The benefit of pioglitazone in patients with diabetes mellitus type 2 and cardiovascular complications].
Olsovský J
Vnitr Lek; 2005 Dec; 51(12):1412. PubMed ID: 16430111
[No Abstract] [Full Text] [Related]
2. [Treatment of patients with type 2 diabetes mellitus with pioglitazone. A survey of a Cochrane review].
Madsbad S
Ugeskr Laeger; 2007 Nov; 169(47):4054-7. PubMed ID: 18078659
[No Abstract] [Full Text] [Related]
3. Implications of rosiglitazone and pioglitazone on cardiovascular risk in patients with type 2 diabetes mellitus.
Irons BK; Greene RS; Mazzolini TA; Edwards KL; Sleeper RB
Pharmacotherapy; 2006 Feb; 26(2):168-81. PubMed ID: 16466323
[TBL] [Abstract][Full Text] [Related]
4. Pioglitazone/glimepiride (Duetact) for diabetes.
Med Lett Drugs Ther; 2007 Jan; 49(1253):9-11. PubMed ID: 17261966
[No Abstract] [Full Text] [Related]
5. Pioglitazone + glimepiride: a combination product to avoid.
Prescrire Int; 2007 Aug; 16(90):145. PubMed ID: 17724836
[No Abstract] [Full Text] [Related]
6. Thiazolidinediones: effects on the development and progression of type 2 diabetes and associated vascular complications.
Krentz A
Diabetes Metab Res Rev; 2009 Feb; 25(2):112-26. PubMed ID: 19219860
[TBL] [Abstract][Full Text] [Related]
7. Pioglitazone/metformin (Actoplus met).
Med Lett Drugs Ther; 2006 Jan; 48(1227):9-11. PubMed ID: 16444136
[No Abstract] [Full Text] [Related]
8. The value equation for rosiglitazone and pioglitazone in older persons.
Zarowitz BJ
Geriatr Nurs; 2008; 29(1):9-11. PubMed ID: 18267172
[No Abstract] [Full Text] [Related]
9. Effect of pioglitazone on the drivers of cardiovascular risk in type 2 diabetes.
Donnelly R
Int J Clin Pract; 2007 Jul; 61(7):1160-9. PubMed ID: 17511791
[TBL] [Abstract][Full Text] [Related]
10. Thiazolidinediones in type 2 diabetes: a cardiology perspective.
Khanderia U; Pop-Busui R; Eagle KA
Ann Pharmacother; 2008 Oct; 42(10):1466-74. PubMed ID: 18698014
[TBL] [Abstract][Full Text] [Related]
11. [Pioglitazone in evaluation by IQWiG (Institute for Quality and Cost Effectiveness in Public Health)--tunnel vision instead of broad view].
MMW Fortschr Med; 2008 Aug; 150(32-35):56-7. PubMed ID: 19009700
[No Abstract] [Full Text] [Related]
12. Thiazolidinediones.
Mascitelli L; Pezzetta F
N Engl J Med; 2005 Jan; 352(2):205-7; author reply 205-7. PubMed ID: 15651125
[No Abstract] [Full Text] [Related]
13. [The PPARgamma receptor agonists and prevention of cardio-vascular complications in patients with type 2 diabetes. The results of the PROactive study].
Szymborska-Kajanek A; Strojek K
Kardiol Pol; 2006 Mar; 64(3):322-5; discussion 325-6. PubMed ID: 16583340
[No Abstract] [Full Text] [Related]
14. [Pioglitazone].
Aso Y
Nihon Rinsho; 2012 May; 70 Suppl 3():620-6. PubMed ID: 22768588
[No Abstract] [Full Text] [Related]
15. A lesson in moderation: applying pharmacodynamics to clarify the relationship between thiazolidinediones and adverse vascular outcomes in type 2 diabetes.
Lehmann DF; Lohray BB
J Clin Pharmacol; 2008 Aug; 48(8):999-1002. PubMed ID: 18650500
[No Abstract] [Full Text] [Related]
16. [Glitazones critically evaluated].
Schernthaner G
Dtsch Med Wochenschr; 2007 Dec; 132(49):2619. PubMed ID: 18050024
[No Abstract] [Full Text] [Related]
17. [Glitazones--again].
Halse J
Tidsskr Nor Laegeforen; 2007 Oct; 127(20):2707; author reply 2707. PubMed ID: 17952161
[No Abstract] [Full Text] [Related]
18. [Too positive comment on glitazones].
Lindberg M
Ugeskr Laeger; 2007 Feb; 169(8):733; author reply 733. PubMed ID: 17338040
[No Abstract] [Full Text] [Related]
19. Pioglitazone-induced progressive pancytopenia.
Favre G; Valnet-Rabier MB; Brousse A; Lepiller Q; Kantelip JP
Ann Pharmacother; 2011 Jan; 45(1):131-3. PubMed ID: 21205948
[No Abstract] [Full Text] [Related]
20. [The true place of glitazones in the treatment of diabetes: after the PROactive study].
Lindberg M; Jørgensen PH; Kampmann JP
Ugeskr Laeger; 2006 Jun; 168(25):2477-9; author reply 2479-80. PubMed ID: 16824389
[No Abstract] [Full Text] [Related]
[Next] [New Search]
